leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...154155156157158159160161162163164...235236»
  • ||||||||||  Trial completion date, Metastases:  Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) -  Apr 16, 2020   
    P2,  N=50, Active, not recruiting, 
    Trial completion date: Mar 2020 --> Aug 2020
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
    Clinical, Journal:  Recurrence and Cancer-Specific Death After Adjuvant Chemotherapy for Stage III Colon Cancer. (Pubmed Central) -  Apr 15, 2020   
    These findings question the routine use of chemotherapy after complete mesocoloic excision for stage III colon cancer. Recurrence and cancer-specific death, assessed by competing risks methods, should be the standard outcomes for evaluating the effectiveness of adjuvant chemotherapy after potentially curative resection.
  • ||||||||||  Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Apr 12, 2020   
    P2,  N=4, Terminated, 
    Active, not recruiting --> Completed N=60 --> 4 | Trial completion date: Mar 2022 --> Apr 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2022 --> Apr 2020; the study was closed early due to competing trials
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
    Journal:  Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. (Pubmed Central) -  Apr 10, 2020   
    The results of this study demonstrated for the first time that cancer-induced and chemotherapy-induced cachexia is characterized by a number of distinct metabolic derangements. Effective therapeutic interventions for cancer-induced and chemotherapy-induced cachexia must take into account the specific metabolic defects imposed by the pathological or pharmacological drivers of cachexia.
  • ||||||||||  EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
    Trial completion date, Trial primary completion date, Metastases:  EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX (clinicaltrials.gov) -  Apr 10, 2020   
    P3,  N=218, Recruiting, 
    On the basis of our results, we consider mFLOX a low-cost option for conversion chemotherapy among other options that have been proposed. Trial completion date: Jul 2020 --> Jun 2022 | Trial primary completion date: Dec 2019 --> Jun 2021
  • ||||||||||  oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Enrollment closed, Trial completion date, Combination therapy:  A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers (clinicaltrials.gov) -  Apr 9, 2020   
    P1,  N=25, Active, not recruiting, 
    Starting intrathecal chemotherapy at minimum effective dose should be considered. Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Jun 2023
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Trial completion date, Trial primary completion date:  A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma (clinicaltrials.gov) -  Apr 6, 2020   
    P1,  N=24, Not yet recruiting, 
    Completed --> Active, not recruiting Trial completion date: Nov 2020 --> Nov 2022 | Trial primary completion date: Nov 2019 --> Jul 2022
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
    Reimbursement, Journal, Medicare:  FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. (Pubmed Central) -  Apr 4, 2020   
    Several demographic and clinical factors were associated with the use of each specific regimen. No survival difference was detected for the 2 groups.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), leucovorin calcium / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    MEDICAL PARADOX: AUTOIMMUNE ENCEPHALITIS IN AN IMMUNOCOMPROMISED PATIENT UNDERGOING ALL CHEMOTHERAPY () -  Apr 3, 2020 - Abstract #ASPHO2020ASPHO_242;    
    AIE has not previously been described in the setting of ongoing multi-agent chemotherapy. However, given the sudden onset and rapid progression of symptoms, longitudinally evolving clinical signs, and existence of antibody negative AIE the early recognition and treatment defined by objective clinical and radiological approach is important.
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    HIGH DOSE METHOTREXATE USE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN A MIDDLE INCOME COUNTRY () -  Apr 3, 2020 - Abstract #ASPHO2020ASPHO_173;    
    Real-time algorithm-based individualized HDMTX monitoring and infusion adjustments was effective without any significant high grade toxicities. To our knowledge, this is the first implementation of this type of HDMTX protocol in low-middle income countries.
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    DELAYED METHOTREXATE EXCRETION DUE TO SEQUESTRATION IN A THYMIC CYST () -  Apr 3, 2020 - Abstract #ASPHO2020ASPHO_97;    
    This case study brings to light a very rare occurrence of MTX sequestration within a pre-existing benign thymic cyst, leading to prolonged time to MTX clearance and hence prolonged hospitalization requiring extended leucovorin rescue. It would be prudent to consider imaging patients with persistent delayed MTX excretion, looking for unusual areas where 3rd spacing may occur, like the thymic cyst in our case.
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    ACCURACY OF HIGH-DOSE METHOTREXATE ADMINISTRATION IN MANAGEMENT OF PEDIATRIC PATIENTS WITH ALL () -  Apr 3, 2020 - Abstract #ASPHO2020ASPHO_19;    
    In particular, methotrexate and creatinine levels are often not measured when indicated, which may affect hydration dosing, and urine pH is often not measured during treatment, which may affect bicarbonate administration. These findings are valuable in informing educational or technological efforts to facilitate more accurate HDMTX management.
  • ||||||||||  Biomarker, Journal:  FOLFOXIRI plus biologics in advanced colorectal cancer. (Pubmed Central) -  Apr 1, 2020   
    FOLFOXIRI-bevacizumab has the widest data from two large randomized phase III trials, being an option to be used in both the palliative and the conversion-therapy settings...Data on response rates and secondary resection rates are promising with the FOLFOXIRI-anti-EGFR combinations and may constitute a valuable option. Results of ongoing head-to-head studies will shed additional light on this issue.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment (clinicaltrials.gov) -  Apr 1, 2020   
    P4,  N=70, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=50 --> 70 | Trial completion date: Jul 2018 --> Jan 2020 | Trial primary completion date: Apr 2018 --> Jun 2019
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Clinical, Journal:  Methotrexate overdose in clinical practice. (Pubmed Central) -  Mar 31, 2020   
    Recruiting --> Completed | N=50 --> 70 | Trial completion date: Jul 2018 --> Jan 2020 | Trial primary completion date: Apr 2018 --> Jun 2019 In accordance with the dictum "prevention is better than cure", the author emphasizes on the role of patient education, regular clinical observation, and laboratory monitoring for prompt recognition and diagnosis of methotrexate overdosing at the earliest stage.